Expert Interview
A third discussion on the NASH treatment landscape and the potential of Altimmune's phase 1 study of pemvidutide, a GLP-1/glucagon dual receptor agonist.
Ticker(s): ALT, LLY, NVOInstitution: Northwestern University
- Internal medicine physician with almost 20 years of experience who treats 20 patients with NASH
- Clinical focus in Women's health
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
